PRO MEDICUS LIMITED (PME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PME - PRO MEDICUS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.02
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Pro Medicus is an imaging IT company providing a range of radiology software and services, medical accounting and clinical reporting to the health care sector. Founded in 1983, the company listed on the ASX in 2000.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$248.83

02 Dec
2024

-3.060

OPEN

$251.83

-1.21%

HIGH

$252.38

285,496

LOW

$243.00

TARGET
$155.30 -37.6% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
PME: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 79.3 104.3 xxx
DPS (cps) xxx 40.0 52.0 xxx
EPS Growth xxx 36.5% 31.6% xxx
DPS Growth xxx 33.3% 29.9% xxx
PE Ratio xxx N/A 246.1 xxx
Dividend Yield xxx N/A 0.2% xxx
Div Pay Ratio(%) xxx 50.5% 49.8% xxx

Dividend yield today if purchased 3 years ago: 0.69%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.16

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/09 - ex-div 22c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx79.3
DPS All xxxxxxxxxxxxxxx40.0
Sales/Revenue xxxxxxxxxxxxxxx161.5 M
Book Value Per Share xxxxxxxxxxxxxxx179.8
Net Operating Cash Flow xxxxxxxxxxxxxxx86.8 M
Net Profit Margin xxxxxxxxxxxxxxx51.27 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx50.72 %
Return on Invested Capital xxxxxxxxxxxxxxx50.30 %
Return on Assets xxxxxxxxxxxxxxx36.03 %
Return on Equity xxxxxxxxxxxxxxx50.72 %
Return on Total Capital xxxxxxxxxxxxxxx67.94 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx49.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx155 M
Price To Book Value xxxxxxxxxxxxxxx79.69

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx6.7 M
Capex % of Sales xxxxxxxxxxxxxxx4.14 %
Cost of Goods Sold xxxxxxxxxxxxxxx39 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx10 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx7 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.4

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

28/11/2024

5

Sell

$100.00

-59.81%

Pro Medicus announced a $24m five-year contract upgrade with NY University Langone Health. The new contract is for the Archive and Worklist modules and will be additive to the existing contract for Viewer originally signed for 7 years in Sept-2020.

That contract was also extended by a year, so both contracts expire in 2029. This new contract shows customers' willingness to not only extend their existing contract, Citi notes, but to also take on the other two major modules, Archive and Worklist.

This is the first new contract for Pro Medicus in FY25. Citi forecasts $30m in new business to be won in FY25 and significant market share gains to the end of the decade, but valuation is keeping the broker on Sell, with an unchanged $100 target.

FORECAST
Citi forecasts a full year FY25 dividend of 50.10 cents and EPS of 100.20 cents.
Citi forecasts a full year FY26 dividend of 64.10 cents and EPS of 128.30 cents.

Macquarie

xx/xx/xxxx

3

xxxxxxxxx xx xxxxxxx xxxx xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Goldman Sachs

02/12/2024

1

Buy

$221.00

-11.18%

Highlighting the ongoing shift to cloud Picture Archiving and Communication Systems (PACS) across the industry, Goldman Sachs notes Pro Medicus has won a full-stack 10-year contract with Trinity Health in the US, valued at $330m, its largest contract to date.

Trinity operates in 26 states with 93 hospitals and over 9k physicians, including circa 650 radiologists. The contract is the first new customer win, excluding renewals and upgrades, in FY25, bringing forth a minimum $33m annualised value.

The broker believes the company's Visage 7 software is an industry-leading solution, with speed and cloud capabilities separating it from the competition. Pro Medicus is also moving into adjacent solutions in cardiology and AI, offering potential significant upside.

Buy rated. Target price $221.

FORECAST
Goldman Sachs forecasts a full year FY25 dividend of 54.00 cents and EPS of 107.00 cents.
Goldman Sachs forecasts a full year FY26 dividend of 69.00 cents and EPS of 136.00 cents.

Moelis

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

PME STOCK CHART

FNArena News on PME

1
Australian Broker Call *Extra* Edition – Dec 02, 2024

Dec 02 2024 - Daily Market Reports
2
Rudi’s View: Trump Beneficiaries & TechOne

Nov 28 2024 - Rudi's View
3
Australian Broker Call *Extra* Edition – Nov 28, 2024

Nov 28 2024 - Daily Market Reports
4
Rudi’s View: Confidence In Quality Rewarded

Nov 27 2024 - Rudi's View
5
Rudi’s View: The Importance Of ‘Quality’ Growth

Nov 21 2024 - Rudi's View

Latest Medical Equipment & Devices News

1
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
2
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
3
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
4
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps
5
ResMed Silences The Doubters

Apr 29 2024 - Australia
6
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
7
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
8
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
9
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View
10
Dr Boreham’s Crucible: Artrya

Feb 15 2024 - Small Caps